Powered by Atman Health
Deo Medical Cardiology
Condition · Heart Failure

Heart Failure

Heart failure is no longer the slow downhill diagnosis it used to be. The last decade brought four classes of medication with strong outcomes evidence — the so-called four pillars of guideline-directed medical therapy — that, used together, substantially extend survival and quality of life. Modern heart-failure management is largely about getting all four pillars on board, tuned to the right doses, and reassessed over time. Virtual cardiology is well-suited to that ongoing titration work.

Dr. Rahul C. Deo Reviewed by Rahul C. Deo, MD, PhD · Last updated May 20, 2026

What heart failure actually is

Heart failure is not a single disease. It is a syndrome — a pattern of symptoms (breathlessness, fatigue, fluid retention) caused by the heart's inability to meet the body's demands for blood flow. The underlying causes range widely: prior heart attack, long-standing hypertension, valve disease, cardiomyopathy, infiltrative disorders (amyloidosis, hemochromatosis), and others. Modern management starts by identifying the cause and then layering on the evidence-based medications that treat the syndrome itself.

HFrEF vs HFpEF

The most important distinction in modern heart-failure care:

The four pillars of HFrEF management

Modern HFrEF treatment is built around four medication classes, each with independent mortality benefit, all to be used together when tolerated:

1. ARNI (sacubitril/valsartan, Entresto)

The PARADIGM-HF trial showed sacubitril/valsartan reduced cardiovascular death and heart-failure hospitalization by ~20% compared with enalapril. It has replaced older ACE inhibitors and ARBs as first-line for HFrEF in patients who can tolerate it. ACE inhibitors and ARBs remain useful when ARNI is not feasible.

2. Beta blockers

Carvedilol, metoprolol succinate, and bisoprolol are the three with HFrEF outcomes data. Started at low doses and titrated up over weeks. Reduce mortality by ~30% in HFrEF, independent of other therapies.

3. Mineralocorticoid receptor antagonist (MRA)

Spironolactone or eplerenone. Adds further mortality benefit on top of ARNI and beta blocker. Requires monitoring of potassium and kidney function.

4. SGLT2 inhibitor

Empagliflozin or dapagliflozin. Originally developed for diabetes, now established for HFrEF (and HFpEF) regardless of diabetes status. Reduces hospitalization and mortality; well-tolerated.

The literature is clear that all four pillars together outperform any one or two alone. Getting all four on board at target doses (or maximum tolerated) is the central optimization work in HFrEF.

HFpEF — the changing picture

HFpEF management was historically frustrating — most HFrEF medications did not translate to HFpEF benefit. That has changed:

What virtual cardiology heart-failure management looks like

  1. First visit by video. Detailed history, review of prior records, echocardiogram, labs, ECG. Establish classification (HFrEF vs HFmrEF vs HFpEF), confirm the underlying cause if known.
  2. Initiate or optimize GDMT. Start the missing pillars; titrate the existing ones.
  3. Titration visits every 2-4 weeks. Review home weights and BP, repeat labs (kidney function, potassium, BNP), adjust doses.
  4. Maintenance visits every 3-6 months once stable. With interim contact if symptoms worsen or weights climb.

Patients with implantable devices (ICDs, CRT-D), severe disease, or considerations for advanced therapies (LVAD, transplant) are co-managed with a local heart-failure specialist as needed.

The bottom line

Heart failure done well — with all four pillars titrated to target, comorbidities optimized, and home monitoring in place — is a very different disease from heart failure managed incompletely. The leverage on outcomes is large. The virtual cardiology model fits because most of the ongoing work is exactly the kind of structured medication titration and home-data review that runs cleanly by video.

Frequently Asked Questions

Common questions

What is the difference between HFrEF and HFpEF?

Heart failure is divided by the heart's pumping function, measured as the ejection fraction (EF) on echocardiogram. HFrEF — heart failure with reduced ejection fraction — means EF under 40%; the heart muscle is weak. HFpEF — heart failure with preserved ejection fraction — means EF over 50% with heart-failure symptoms; the heart muscle pumps normally but is stiff and doesn't fill well. The treatments differ: HFrEF has a richer evidence base (the four-pillar GDMT framework), while HFpEF has gained important new options recently (SGLT2 inhibitors).

What are the four pillars of guideline-directed medical therapy?

For HFrEF: (1) an ARNI (sacubitril/valsartan, brand name Entresto) — replaces older ACE inhibitors and ARBs as first-line; (2) a beta blocker — carvedilol, metoprolol succinate, or bisoprolol; (3) a mineralocorticoid receptor antagonist (MRA) — spironolactone or eplerenone; (4) an SGLT2 inhibitor — empagliflozin or dapagliflozin. Each has independent mortality benefit. Getting all four on board at target doses (or maximum tolerated) is the central work of HFrEF management.

What symptoms should I watch for at home?

The key things to track: daily weight (a 2-3 pound gain in 1-2 days suggests fluid retention), breathlessness with activity or lying flat, leg swelling, fatigue out of proportion to activity, and any new chest discomfort or palpitations. Worsening of any of these is a reason to contact your cardiologist — early intervention with diuretic adjustment can often head off a hospitalization. Many patients track weight on a chart shared with their cardiologist by photo or app.

Can virtual cardiology really manage heart failure?

Yes — much of heart failure management is exactly the kind of ongoing titration and monitoring that fits virtual care well. Medication adjustments, lab monitoring (kidney function, potassium, BNP), home weight tracking, symptom review, lifestyle reinforcement — all work cleanly by video. The pieces that need in-person care (electrical cardioversion for AFib, implantable devices, advanced therapies like ventricular assist devices or transplant evaluation) are coordinated with local specialists when needed.

How often will I see my cardiologist with heart failure?

During initial titration of GDMT, every 2-4 weeks is typical as we titrate doses, monitor labs, and confirm tolerability. Once a stable regimen is in place, every 3-6 months is usual for ongoing maintenance. Decompensations (weight gain, increased symptoms) may need a quick interim visit. The home-weight-tracking and BP-tracking habits patients develop make these between-visit conversations efficient.

Related
Condition

Atrial Fibrillation

AFib management — rhythm vs rate control, stroke-risk prevention, and what to expect with a cardiologist.
Condition

High Cholesterol

When LDL or apoB is elevated — what the numbers mean, what testing helps, and how treatment is decided.
Condition

Hypertension

Diagnosing and treating high blood pressure — from home monitoring to medication selection.
Condition

Valve Disease

Aortic, mitral, and other valvular conditions — how a cardiologist monitors severity and decides when to intervene.

Concerned about heart failure?

Book a virtual visit with a board-certified, Harvard-trained cardiologist. Most appointments within a week.

Book a Virtual Visit